These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19808642)

  • 1. Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands.
    Chung ES; Chauhan SK; Jin Y; Nakao S; Hafezi-Moghadam A; van Rooijen N; Zhang Q; Chen L; Dana R
    Am J Pathol; 2009 Nov; 175(5):1984-92. PubMed ID: 19808642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
    Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
    Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
    Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
    Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling.
    Tammela T; Zarkada G; Nurmi H; Jakobsson L; Heinolainen K; Tvorogov D; Zheng W; Franco CA; Murtomäki A; Aranda E; Miura N; Ylä-Herttuala S; Fruttiger M; Mäkinen T; Eichmann A; Pollard JW; Gerhardt H; Alitalo K
    Nat Cell Biol; 2011 Sep; 13(10):1202-13. PubMed ID: 21909098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity.
    Leppänen VM; Jeltsch M; Anisimov A; Tvorogov D; Aho K; Kalkkinen N; Toivanen P; Ylä-Herttuala S; Ballmer-Hofer K; Alitalo K
    Blood; 2011 Feb; 117(5):1507-15. PubMed ID: 21148085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1.
    Flister MJ; Wilber A; Hall KL; Iwata C; Miyazono K; Nisato RE; Pepper MS; Zawieja DC; Ran S
    Blood; 2010 Jan; 115(2):418-29. PubMed ID: 19901262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphangiogenesis in aortic valve stenosis--novel regulatory roles for valvular myofibroblasts and mast cells.
    Syväranta S; Helske S; Lappalainen J; Kupari M; Kovanen PT
    Atherosclerosis; 2012 Apr; 221(2):366-74. PubMed ID: 22281299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
    Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
    J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronan-induced VEGF-C promotes fibrosis-induced lymphangiogenesis via Toll-like receptor 4-dependent signal pathway.
    Jung YJ; Lee AS; Nguyen-Thanh T; Kang KP; Lee S; Jang KY; Kim MK; Kim SH; Park SK; Kim W
    Biochem Biophys Res Commun; 2015 Oct; 466(3):339-45. PubMed ID: 26362177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analyses of the bone marrow kinase in the X chromosome in vascular endothelial growth factor-induced lymphangiogenesis.
    Jones D; Xu Z; Zhang H; He Y; Kluger MS; Chen H; Min W
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2553-61. PubMed ID: 20864667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphangiogenesis-independent resolution of experimental edema.
    Ongstad EL; Bouta EM; Roberts JE; Uzarski JS; Gibbs SE; Sabel MS; Cimmino VM; Roberts MA; Goldman J
    Am J Physiol Heart Circ Physiol; 2010 Jul; 299(1):H46-54. PubMed ID: 20207821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
    Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.
    Wuest TR; Carr DJ
    J Exp Med; 2010 Jan; 207(1):101-15. PubMed ID: 20026662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas.
    Jenny B; Harrison JA; Baetens D; Tille JC; Burkhardt K; Mottaz H; Kiss JZ; Dietrich PY; De Tribolet N; Pizzolato GP; Pepper MS
    J Pathol; 2006 May; 209(1):34-43. PubMed ID: 16523449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis.
    Hos D; Regenfuss B; Bock F; Onderka J; Cursiefen C
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5778-85. PubMed ID: 21666240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.